Clinical trials: Dual Antiplatelet Therapy
Acute Stroke, Dual Antiplatelet Therapy
Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
Branch atheromatous disease (BAD) has been reported to contribute to small-vessel occlusion and is associated with a higher possibility of early neurological deterioration (END).
- Conditions
- Acute Stroke, Dual Antiplatelet Therapy, Statin
- Trial name
- SATBRAD (NCT04824911)
- Testing
- Clopidogrel, Aspirin, Atorvastatin
- Where
- Taiwan
- Volunteers
- 376 people
- Sponsor
- Chang Gung Memorial Hospital
Stable Angina Pectoris, Coronary Artery Disease
1 or 6 Months of Dual Antiplatelet Therapy After Drug-coated Balloon Angioplasty for De-novo Small Coronary Artery Disease
1. Objective Objective: > The purpose of this study is to evaluate whether a short-term (1-month) dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) is non-inferior to the standard 6-month DAPT in…
- Trial name
- D-ONE (NCT07592507)
- Testing
- 1-Month DAPT followed by SAPT, 6-Month DAPT followed by SAPT
- Volunteers
- 1,484 people
- Sponsor
- Daejeon St. Mary's hospital
Ischemic Heart Disease
Clopidogrel Versus Aspirin MOnotherapy After 1- to 3-month of Dual-antiplatelet thErapy Following Zotarolimus-eluting Onyx Stents Implantation; C-MODE Trial
Previous randomized clinical trials have deomonstrated the efficacy and safety of short-term dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI), however, the single antiplatelet agent to be maintained…
- Trial name
- NCT05320926
- Testing
- Clopidogrel monotherapy, Aspirin monotherapy, zotarolimus-eluting stent (Resolute Onyx ®)
- Where
- South Korea
- Volunteers
- 3,744 people
- Sponsor
- Yonsei University
Ruptured Intracranial Aneurysms, Subarachnoid Hemorrhage, Aneurysmal
The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent
This multicenter prospective randomized controlled study will enroll patients with ruptured intracranial aneurysms receiving stent-assisted coiling across multiple Chinese medical centers.
- Trial name
- TEARIAS (NCT07818083)
- Testing
- Tirofiban+Oral Dual Antiplatelet Therapy, Dual Antiplatelet Therapy plus Normal Saline
- Volunteers
- 622 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Coronary Artery Disease, Depression
Antiplatelet Therapies in Patients With Depression and Coronary Disease
Depression after an acute coronary syndrome (ACS) but also at any time after CAD diagnosis, is highly associated with death, and it predicts mortality more than any other risk factor, comorbidity or follow-up events, suggesting…
- Trial name
- ENHANCE (NCT05821062)
- Testing
- standard Aspirin (ASA) + clopidogrel (CLP) therapy, standard Aspirin (ASA) + Ticagrelor (TCG) or Prasugrel (PSG) therapy, standard ASA therapy
- Where
- 2 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Centro Cardiologico Monzino
STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI
HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study
The aim of this study is to determine the prevalence of Helicobacter pylori (Hp) infection in patients with myocardial infarction (MI).
- Trial name
- HELPpilot (NCT04289012)
- Testing
- Helicobacter Pylori screening by UBT
- Where
- 2 sites in Sweden
- Volunteers
- 300 people
- Sponsor
- Karolinska Institutet
Coronary Artery Disease
EVOLVE Short DAPT Study
The EVOLVE Short DAPT Study is a prospective, multicenter, single-arm study designed to assess the safety of 3-month DAPT in subjects at high risk for bleeding undergoing PCI with a SYNERGY Stent System.
- Trial name
- NCT02605447
- Testing
- 3 months of dual antiplatelet therapy (DAPT), SYNERGY Stent System
- Where
- 110 sites in United States, Brazil and 5 more
- Volunteers
- 2,009 people
- Sponsor
- Boston Scientific Corporation
Cardiopulmonary Bypass, Platelet Disorder
Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass
Patients admitted for coronary artery bypass surgery taking antiplatelet medicine have an increased risk for bleeding. Present study aims to compare the platelet function in two patient groups using different types of heart-lung…
- Conditions
- Cardiopulmonary Bypass, Platelet Disorder, Bleeding Disorder, Platelet Dysfunction Due to Drugs
- Trial name
- NCT02979158
- Testing
- CPB Low Dose, CPB High Dose
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Umeå University
Myocardial Infarction, Myocardial Fibrosis
Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction
This is a single-center, prospective, observational controlled cohort study designed to describe the role of WNT/B-catenin signaling and adenosine system after an acute myocardial infarction, correlating it with clinical markers…
- Conditions
- Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular
- Trial name
- BETA-MI (NCT05122741)
- Testing
- P2Y12 Potent Inhibitor + Aspirin for STEMI patients, Clopidogrel + Aspirin for CCS patients
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Messina
Acute Coronary Syndrome
Registry of Acute Coronary Syndrome From University Hospital of Vigo
CardoCHUVI registry was aim to study ischemic and bleeding complication after an acute coronary syndrome (ACS), both in-hospital and follow-up events.
- Trial name
- CardioCHUVI (NCT03664388)
- Testing
- Dual antiplatelet therapy with ticagrelor/prasuglre
- Where
- Spain
- Volunteers
- 8,000 people
- Sponsor
- Hospital Álvaro Cunqueiro
Coronary Artery Disease
The Optimal Duration of Dual Antiplatelet Therapy After Implantation of Endeavor Stent
The purpose of this study to determine whether the dual antiplatelet therapy (aspirin and clopidogrel) for 3 months after coronary implantation of zotarolimus-eluting stent is safe in terms of death, myocardial infarction, or…
- Trial name
- DATE (NCT00418860)
- Testing
- Aspirin, Clopidogrel
- Where
- South Korea
- Volunteers
- 1,200 people
- Sponsor
- Samsung Medical Center
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors" -Trial dOPPLER-
Clopidogrel and Prasugrel are pro-drug necessitating conversion in active metabolites through CYP 450 system (CYP), particularly CYP3A and CYP2C19 isoforms.
- Trial name
- dOPPLER (NCT02028234)
- Testing
- Pantoprazole,, Omeprazole
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- University of Roma La Sapienza
Acute Coronary Syndrome
Rivaroxaban Combined With DAPT Versus DAPT Alone After Drug-coated Balloon Angioplasty
The target population of this interventional study was ACS patients with drug-coated balloons. The main discussion : 1.1 months of rivaroxaban combined with dual antiplatelet therapy compared with dual antiplatelet therapy alone…
- Trial name
- NCT05750758
- Testing
- rivaroxaban
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
Antiplatelet Therapy of Coronary Artery Bypass
A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting
This study is designed to demonstrate that the onset of the antiplatelet effect of 90mg bid dose ticagrelor is more rapid and greater than 75 mg qd dose clopidogrel in patients undergoing CABG surgery.
- Trial name
- ATCCC (NCT02330640)
- Testing
- ticagrelor, clopidogrel, asprin
- Where
- China
- Volunteers
- 137 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Coronary Artery Disease
A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation
DES are preferred over BMS for most patients, however prolonged dual antiplatelet therapy is required for patients treated with DES for prevention of late or very late stent thrombosis. which increases a risk of major bleeding.
- Trial name
- NCT02513810
- Testing
- BioFreedom with 1 month DAPT, BioMatrix or Ultimaster with 6 to 12 months DAPT
- Where
- South Korea
- Volunteers
- 3,020 people
- Sponsor
- Yonsei University
Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement
Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI
TAVI is increasingly adopted as standard treatment for many subgroups of patients with aortic stenosis. However, due to a lack of data there is yet no TAVI-specific guidance regarding the optimum periinterventional drug regimen.
- Conditions
- Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Intracranial Embolism
- Trial name
- DAPT-TAVI (NCT03001960)
- Testing
- Preloading before TAVI, Postloading after TAVI
- Volunteers
- 200 people
- Sponsor
- Charite University, Berlin, Germany
Acute or Programmed Hip Replacement (Gamma Nail, Total Prosthesis or Throuhg DHS) / Knee Surgery
Assessment of Blood Loss With a Point Of Care Device
Main Objective: The purpose of this study is to demonstrate whether there is a correlation between perioperative blood loss and the degree of platelet inhibition assessed by a point of care assay in patients undergoing hip or…
- Trial name
- BLOOD (NCT01430273)
- Where
- 3 sites in France
- Volunteers
- 28 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Coronary Artery Disease
Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting
The purpose of this study is to determine whether a 6 month duration of clopidogrel therapy after DES implantation is not inferior to that of a 12 month therapy.
- Trial name
- ISAR-SAFE (NCT00661206)
- Testing
- Clopidogrel
- Where
- 40 sites in United States, Albania and 11 more
- Volunteers
- 4,005 people
- Sponsor
- Deutsches Herzzentrum Muenchen